[ 1 ] Scagliotti G, Novello S, von Pawel J, et al. PhaseⅢ study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(11): 1835-1842.
[2]
[ 2 ] Mcdermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phaseⅡ study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group[J]. J Clin Oncol, 2008, 26(13): 2178-2185.
[3]
[ 3 ] Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6): 501-513.
[4]
[ 4 ] Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phaseⅢ study[J]. J Clin Oncol, 2012, 30(9): 921-929.
[5]
[ 5 ] Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phaseⅢ, randomized, open-label trial[J]. Clin Breast Cancer, 2011, 11(2): 82-92.
[6]
[ 6 ] Barrios CH, Liu MC, Lee SC, et al. PhaseⅢ randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer[J]. Breast Cancer Res Treat, 2010, 121(1): 121-131.
[7]
[ 7 ] Grávalos C, Grande E, Gasent JM. The potential role of sunitinib in gastrointestinal cancers other than GIST[J]. Crit Rev Oncol Hematol, 2010, 76(1): 36-43.
[8]
[ 8 ] Govidan V, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phaseⅢ trial[J]. J Clin Oncol, 2012, 30(17): 2070-2078.
[9]
[ 9 ] Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction[J]. Blood, 2006, 107(11): 4532-4539.
[10]
Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model[J]. Cancer Res, 2008, 68(9): 3323-3333.
[11]
Montemurro M, Sch？ffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib[J]. Eur J Cancer, 2009, 45(13): 2293-2297.
Lin NU, Diéras V, Paul D, et al. Multicenter phaseⅡ study of lapatinib in patients with brain metastases from HER2-positive breast cancer[J]. Clin Cancer Res, 2009, 15(4): 1452-1459.
[14]
Kim HP, Han SW, Kim SH, et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells[J]. Mol Cancer Ther, 2008, 7(3): 607-615.
[15]
van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2012, 379(9829): 1879-1886.
[16]
Rugo HS, Herbst RS, Liu G, et al. PhaseⅠ trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results[J]. J Clin Oncol, 2005, 23(24): 5474-5483.
[17]
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial[J]. Lancet, 2011, 378(9807): 1931-1939.
[18]
Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms[J]. Blood, 2010, 115(15): 3109-3117.
[19]
Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J]. N Engl J Med, 2012, 366(9): 799-807.
